Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Net Income towards Common Stockholders (2018 - 2019)

Historic Net Income towards Common Stockholders for DiaMedica Therapeutics (DMAC) over the last 2 years, with Q4 2019 value amounting to -$2.5 million.

  • DiaMedica Therapeutics' Net Income towards Common Stockholders fell 2640.16% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 8571.68%. This contributed to the annual value of -$24.4 million for FY2024, which is 2612.35% down from last year.
  • According to the latest figures from Q4 2019, DiaMedica Therapeutics' Net Income towards Common Stockholders is -$2.5 million, which was down 2640.16% from -$2.4 million recorded in Q3 2019.
  • Over the past 5 years, DiaMedica Therapeutics' Net Income towards Common Stockholders peaked at -$650000.0 during Q1 2018, and registered a low of -$3.3 million during Q1 2019.